Flexion Therapeutics
| Public | |
| Traded as | NASDAQ: FLXN |
| Industry | Biotechnology |
| Headquarters | Woburn, MA |
| Website | Flexion Therapeutics |
Flexion Therapeutics is an American biotechnology company based in Burlington, Massachusetts that is developing long-lasting intra-articular injection therapies for the treatment of osteoarthritis.[1][2] As of May 2012 Flexion was developing three new drug candidates:
- FX005 is a sustained release, intra-articular p38 mitogen-activated protein kinase (p38 MAP) inhibitor,[3][4]
- Zilretta (FX006) is a sustained release, intra-articular steroid, that has received FDA Fast Track Designation to treat pain from osteoarthritis of the knee.[5][6]
- FX007 is a sustained release, intra-articular TrkA receptor antagonist.[5]
References
- ↑ Gormley, Brian. (28 November 2011). "Flexion Changes Endgame, Advances Osteoarthritis Drugs." Dow Jones VentureWire.
- ↑ Young, Robin.(8 March 2012)."Could This Be Orthopedics’ Future?" Orthopedics This Week.
- ↑ Jackson, Mandy.(30 May 2012)."Flexion Phase II Data for FX005 gives Clinical PoC in Arthritis Pain." SCRIP.
- ↑ Gormley, Brian. (30 May 2012). "Flexion Therapeutics Raises 13M from insiders, Progresses Pipeline." Dow Jones VentureWire.
- 1 2 Weintraub, Arlene. (30 May 2012). "Flexion Overhaul Bears Fruit With Upbeat Data From Arthritis Trial." Xconomy.
- ↑ Flexion eyes FDA approval after key gains in osteoarthritis-drug trial. Feb 2016
External links
This article is issued from Wikipedia - version of the 2/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.